MG
ANIP icon

Mather Group’s ANI Pharmaceuticals ANIP Stock Holding History

Mather Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.57K Hold
31
– – ﹤0.01% 1707
2026
Q1 		$2.38K Buy
+31
New +$2.42K ﹤0.01% 1677
2025
Q4 		– Sell
-31
Closed -$2.84K – 689
2025
Q3 		$2.84K Buy
+31
New +$2.53K ﹤0.01% 1492
2025
Q2 		– Sell
-31
Closed -$2.08K – 659
2025
Q1 		$2.08K Hold
31
– – ﹤0.01% 1565
2024
Q4 		$1.71K Hold
31
– – ﹤0.01% 1560
2024
Q3 		$1.85K Hold
31
– – ﹤0.01% 1497
2024
Q2 		$2.14K Hold
31
– – ﹤0.01% 1872
2024
Q1 		$1.71K Buy
+31
New +$1.87K ﹤0.01% 1568

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mather Group's ANIP Position: Q2 2026 in Review

Mather Group held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 31 shares worth $2.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1707.

Mather Group first reported a position in ANIP in Q1 2024 and has held it in 8 quarters since. The position peaked at $2.84K in Q3 2025. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Mather Group held 31 shares of ANI Pharmaceuticals worth $2.57K as of Q2 2026.
  • Mather Group left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1707 holding.
  • Mather Group first reported a position in ANI Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's ANI Pharmaceuticals position peaked at $2.84K in Q3 2025.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.